Immunocore
IMCR
57 hedge funds and large institutions have $590M invested in Immunocore in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 19 increasing their positions, 8 reducing their positions, and 8 closing their positions.
8,727% more call options, than puts
Call options by funds: $971K | Put options by funds: $11K
138% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 8
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
16% more funds holding
Funds holding: 49 → 57 (+8)
3.77% more ownership
Funds ownership: 41.23% → 45.01% (+3.8%)
8% less capital invested
Capital invested by funds: $642M → $590M (-$52.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$15.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.96M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.73M |
| 4 |
SC
Samlyn Capital
New York
|
+$9.61M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$9.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.5M |
| 2 |
PA
Perceptive Advisors
New York
|
-$12.3M |
| 3 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
-$9.95M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$9.51M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.81M |
IMCR Hedge Fund Activity: Q1 2022 in Review
57 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q1 2022, worth a combined $590M — down 8.1% from $642M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new IMCR positions and 8 closed out — a net gain of 8 holders — while 19 added to existing stakes and 8 trimmed.
The largest buyer was RTW Investments, adding an estimated $15.5M. The largest seller was Fidelity Investments, cutting an estimated $12.5M.
- 57 institutional investors held Immunocore (IMCR) as of Q1 2022, up from 49 in Q4 2021.
- Funds reported $590M of Immunocore stock for Q1 2022, down 8.1% quarter-over-quarter.
- 16 funds opened new Immunocore positions in Q1 2022 and 8 closed out, a net change of +8 holders.
- The largest Immunocore buyer in Q1 2022 was RTW Investments, an estimated $15.5M added.
- The largest Immunocore seller in Q1 2022 was Fidelity Investments, an estimated $12.5M sold.
Based on aggregated 13F filings for Q1 2022.